Member Info for Saint68

The Tempest surge occurred due to a number of factors and at a different time - ie after phase 1/2 was complete. We've not started yet. Below is the explanation :

While the market capitalization of TPST was over $100 million at one point, as the stock rocketed 4000% higher, the stock had a modest market cap of about $5 million before the move. This micro-cap starting point had positioned the stock to achieve significant percent returns should volume and a catalyst enter the frame.

The biggest contributing factor to the enormous surge was the stock float size relative to the volume traded. The stock is estimated to have a public float of 12.5 million shares, having grown post-dilution. On day one of the breakout in volume and price, the stock traded over 170 million shares. This influx in volume created an enormous supply and demand imbalance, as the float was likely significantly smaller than 12.5 million shares at that point. So, with a lack of supply and a surge in demand, it appeared the stock had nowhere to go but higher on the day.

The final leading factor that contributed to the surge higher is intraday shorts. Intraday shorts threw gasoline on the fire. The supply and demand imbalance existed even without the involvement of short sellers. However, with a wide availability of locates reported for TPST at a reasonably low price, retail short sellers contributed significantly to the imbalance, resulting in a remarkable squeeze higher.

I agree that $47M would indeed provide substantial security but it wouldn't be for many years as clinical trials can be very very costly. Bringing a new therapy to market will need billions not millions. My point was not that we can't get to 25p per share but the way you stated that " if Prevail and Vlad can pull off would see the HEMO share price rocket way past 25p a share" IMO is very misleading. I hope that you will be proved correct but can't see that type of increase until we are deep into phase 1 or get amazing news on CBR.

Brighty1 why would a £47 million licensing deal see the sp rocket to more that 25p ? I would expect a decent raise in SP but stating 25p as if it's a fact is just ramping

Feb 8th for me please

Morning all. Great to see the IND submitted and IMO approval to go clinical is a formality given that the FDA has previously reviewed and only had 1 issue which has now been dealt with. Are we finally about to see true value here - lets hope so.

The cost would vary depending on where you’re based. - England, Wales and Scotland would probably have different costs as they would all have individual contracts with suppliers. Generic Dox is way cheaper than the branded version and the contracts offer significant reductions.

Getting ridiculous on here now. My screen looks like this :-)

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

This message has been filtered, please adjust your filters to view

Parfett - I've seen that monthly figure in the Telegram group but I'm not 100% convinced that it's correct - unless the BOD have taken huge pay cuts.

Do not listen to anyone on this board. Do your own research and invest based on your research.

Do you mean long term whinging trader who constantly moans and groans ?

titanium**** - binned. already enough twats on this bb.

I believe what was in the RNS - see previous message.

I know, so why repost the info if you know it may be incorrect ?

Datta - as previously mentioned, those figures include Rosgeo JV and nobody here knows what's going on with that anymore. Conflicting info on the RNS from 7/12/23 doesn't help.

"With respect to the Nyud project, as the Rosgeo Agreement has expired no further announcements will be made regarding reserves and resources on such assets, which are no longer under the control of the Company"

"Despite a transferrable legal entitlement to the Nyud project remaining in place, no further work on this project is currently planned by the Company."

Hi Layla,

I thought Keith's replacement (and Artem) work for Essar - an Indian company with a base in China. I'm not aware of her connections with Japan but I haven't dug too deeply due to lack of time.

I can see Japan possibly being part of EUA2 (if it happens) but don't think they're part of the sale of our assets. Happy to be wrong as any sale should be good for shareholders.

But we do - it's China and Russia...

Doubtful as it was in an RNS so would need to have been cleared by the Nomad. Lying in an RNS - not a good look.

They have but we've been told via RNS that it's China and Russia. Possibly there for EUA2 (if it happens) but don't think they'll play any part in our sale of assets now.

OOR - I though the interested parties were China and Russia based so where has Japan suddenly come into the mix ?

All for advertising and networking but unless we receive an RNS first he will not be able to divulge any information that could be market sensitive.